Hospital News and Research

RSS

Cell Therapeutics launches Pixuvri in the European Union

Cell Therapeutics, Inc., a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri in the European Union with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012.

11 Sep 2012

Rhode Island receives NIH grant to study cartilage and joint health

Rhode Island Hospital's Center of Biomedical Research Excellence (COBRE) in Skeletal Health and Repair has been awarded a $10.8 million grant from the National Institutes of Health (NIH), one of the largest grants in Rhode Island Hospital history. This grant, to be paid over five years, will fund studies of cartilage and joint health.

11 Sep 2012

AHRQ-funded project reduces rate of central line-associated bloodstream infections in ICUs by 40%

A unique nationwide patient safety project funded by the Agency for Healthcare Research and Quality (AHRQ) reduced the rate of central line-associated bloodstream infections (CLABSIs) in intensive care units by 40 percent, according to the agency's preliminary findings of the largest national effort to combat CLABSIs to date.

11 Sep 2012

P5091 molecule triggers apoptosis in drug-resistant myeloma cells

A molecule that targets the cell's machinery for breaking down unneeded proteins can kill multiple myeloma cancer cells resistant to the frontline drug Velcade, researchers at Dana-Farber Cancer Institute have found.

11 Sep 2012

Flow cytometry renders PCR testing unnecessary for most AML patients

Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research led by St. Jude Children's Research Hospital investigators has identified the best test for measuring that response and guiding therapy.

11 Sep 2012

Combining two drugs may offer new and potent punch against cancer and other diseases

A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal -- such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.

11 Sep 2012

Oxyphenbutazone can kill drug resistant TB

An off-patent anti-inflammatory drug that costs around two cents for a daily dose in developing countries has been found by researchers at Weill Cornell Medical College to kill both replicating and non-replicating drug resistant tuberculosis in the laboratory -- a feat few currently approved TB drugs can do, and resistance to those is spreading.

11 Sep 2012

Partial pressure measures could be used in neonates after surgery

End tidal carbon dioxide and transcutaneous carbon dioxide could be useful to monitor partial pressure of arterial CO2 in neonates after surgery, a study shows.

10 Sep 2012

Complete mitral valve ring repair reduces recurrent regurgitation

Mitral valve repair with complete versus partial ring annuloplasty results in lower levels of recurrence in patients with functional mitral regurgitation, conclude US investigators.

10 Sep 2012

Plasma biomarker predicts rheumatoid arthritis onset

Healthy individuals with high levels of immunoglobulin G rheumatoid factor have a significantly increased risk for developing rheumatoid arthritis, suggests population-based research published in the BMJ.

10 Sep 2012

Pathogens identified in majority of childhood CAP hospitalizations

A comprehensive investigation of childhood community-acquired pneumonia in Taiwan has identified at least one pathogen in 85% of previously healthy children.

10 Sep 2012

Allscripts EHR to be implemented at Coordinated Health

Coordinated Health, a top integrated healthcare delivery network across Pennsylvania and New Jersey, selected Sunrise Clinical Manager from Allscripts to help its clinicians improve care, better manage clinical information, and become more efficient.

10 Sep 2012

Annovation Biopharma to develop novel anesthetics with $8M Series A financing

Annovation Biopharma, a biotechnology company focused on creating more effective, safer therapies for anesthesia and critical care, has raised $8M in a Series A financing led by Atlas Venture, Partners Innovation Fund, and new strategic investor The Medicines Company.

10 Sep 2012

Florida Hospital Tampa adopts FDA approved Trevo Pro Clot Retriever

Florida Hospital Tampa and Dr. James E. Lefler are the first in the Tampa Bay area to adopt the new FDA approved device called the Trevo Pro Clot Retriever manufactured by Stryker. The Trevo Pro is the next generation in clot removal technology.

10 Sep 2012

Physician empathy has positive impact on patient outcomes

Patients of doctors who are more empathic have better outcomes and fewer complications, concludes a large, empirical study by a team of Thomas Jefferson University and Italian researchers who evaluated relationships between physician empathy and clinical outcomes among 20,961 diabetic patients and 242 physicians in Italy.

10 Sep 2012

Adult stem cell technology holds hope for erectile dysfunction treatment

After more than a decade of short-term cures to erectile dysfunction, most aimed at symptoms rather than the underlying issues of nerve damage, a new approach has emerged from adult stem cell technology developed by RNL Bio. Dr. Ji Youl Lee and the RNL Stem Cell Technology Institute (RNL SCTI) team, working at St. Mary's Hospital in Seoul, found in animal studies that adipose (fat) derived adult human stem cells, grown in culture, were very effective in treating cavernous nerve injury.

10 Sep 2012

Islet Sciences licenses noninvasive technology from Winthrop for detecting Beta cell death

Islet Sciences, Inc., a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from Winthrop University Hospital. This technology is complimentary to the early Beta cell destruction diagnostic that Islet Sciences licensed last month.

10 Sep 2012

Increased use of powerful antipsychotic drugs to treat publicly insured children

A national study conducted by researchers at The Children's Hospital of Philadelphia (CHOP) shows increased use of powerful antipsychotic drugs to treat publicly insured children over the last decade. The study, published today in the journal Health Services Research, found a 62 percent increase in the number of Medicaid-enrolled children ages 3 to 18 taking antipsychotics, reaching a total of 354,000 children by 2007.

10 Sep 2012

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.

10 Sep 2012

Concussion: an interview with Dr Rob Reid

Concussion happens when something produces a concussive force to the head, such as a blow to the head. The definition from the 2008 consensus, which was in Zurich, is, “concussion is defined as a complex pathophysiological process affecting the brain, induced by traumatic biomechanical forces.”

10 Sep 2012